-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Vir Biotech today announced a new preclinical study to prove that the company's research SARS-CoV-2 monoclonal antibody VIR-7831 can maintain its neutralizing effect.
In this new study, Vir and Washington University researchers reported on the rapid and exponential growth of the California variant in all 50 states in the United States and 29 other countries around the world, and described the effects of its three mutations: S13I, W152C and L452R.
Data from 43 vaccinated donors and 9 convalescent donors showed that in the pseudotyped virus system, the S13I, W152C, and L452R mutations reduced the neutralization ability of plasma by three to six times.
The researchers also observed that VIR-7831, which targets a non-receptor binding motif (RBM) epitope, is not affected by the L452R mutation.
Original source:
Original source:href="" target="_blank" rel="noopener">